LAUSR

Since its inception in the 1940’s, chemotherapy has remained the standard treatment for many cancers. The morbidity and mortality associated with these drugs have triggered scientists to discover newer methods of treatment such as immunotherapy. Although immunotherapy has proven to be successful in many preclinical and clinical models in cancers such as melanoma, data in poorly immunogenic cancers such as breast cancer continues to be controversial. Several large clinical trials have tested the use of various forms of immunotherapy in breast cancer such as checkpoint inhibitors, adoptive T cell therapy, vaccines and adjunctive immunotherapy, all of which have shown promising results. This review article highlights the advances of immunotherapy in breast cancer and discusses the future research needed to be conducted to unveil the full potential of these drugs.